Table 5

Multivariate regression results for incidence of intensive care unit admission

EstimateSEStatisticP valueOROR SE
Patient characteristics
Male gender0.110.120.890.371.120.28
Charlson Comorbidity Index (excluding cancer)
Immune checkpoint inhibitor use
CTLA4 therapy0.360.251.470.141.440.29
Combination ICI therapy0.210.220.960.341.230.46
Underlying conditions
Other cancer0.110.170.670.51.120.24
Renal cell carcinoma0.110.20.550.581.120.03
Regional information
Zip code average income (normalized)
Zip code average unemployment (normalized)
East South Central
New England−0.580.37−1.560.120.560.21
South Atlantic−0.10.21−0.480.630.910.17
West North Central0.110.350.310.761.110.27
West South Central0.220.2210.321.240.37
  • Note: reference group is female patients on programmed cell death protein 1or programmed death-ligand 1 therapy with Lung Cancer in East North Central Region.

  • Other cancers include: bladder cancer, colon cancer, head and neck squamous cell carcinoma Hodgkin’s lymphoma, gastric cancer, liver cancer, cervical cancer, and Merkel cell carcinoma.

  • CTLA4, cytotoxic T lymphocyte-associated 4; ICI, immune checkpoint inhibitor.